Literature DB >> 2113797

Steady-state pharmacokinetics of fleroxacin in patients with skin and skin structure infections.

K Heim-Duthoy1, G Peltier, W Awni.   

Abstract

Steady-state pharmacokinetics of oral fleroxacin were studied in six males who had skin or skin structure infections and who were receiving 400 mg of fleroxacin once a day. Blood samples (n = 10) and total urine output were collected during a 24-h dosing interval. Fleroxacin concentrations in serum and urine were determined by high-performance liquid chromatography. The maximum concentration in serum and the time to achieve that maximum were 6.2 +/- 2.2 micrograms/ml and 0.94 +/- 0.62 h, respectively. The absorption half-life, alpha half-life, beta half-life, apparent steady-state volume of distribution, apparent total body clearance, and renal clearance were 0.56 +/- 0.37 h, 0.78 +/- 0.51 h, 10.56 +/- 1.40 h, 0.85 +/- 0.31 liters/kg, 129.2 +/- 19.6 ml/min, and 53.3 +/- 16.7 ml/min, respectively. Fleroxacin disposition in this patient population was similar to that in noninfected volunteers with normal renal function.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2113797      PMCID: PMC171722          DOI: 10.1128/AAC.34.5.922

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  Pharmacokinetics and tissue penetration of Ro 23-6240, a new trifluoroquinolone.

Authors:  R Wise; B Kirkpatrick; J Ashby; D J Griggs
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

2.  Comparative in-vitro activity of Ro 23-6240, a new trifluorinated quinolone.

Authors:  L Verbist
Journal:  J Antimicrob Chemother       Date:  1987-09       Impact factor: 5.790

3.  Pharmacokinetics of ceftazidime and netilmicin in patients with sepsis.

Authors:  U Ganzinger; G Kleinberger; K Lenz; F Schatz; A Laggner; G Grimm
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1987-07

4.  Steady-state pharmacokinetics of imipenem in febrile neutropenic cancer patients.

Authors:  G L Drusano; K I Plaisance; A Forrest; C Bustamante; A Devlin; H C Standiford; J C Wade
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

5.  Multiple-dose pharmacokinetics of the monobactam azthreonam (SQ 26,776) in healthy subjects.

Authors:  E A Swabb; A A Sugerman; D N McKinstry
Journal:  Antimicrob Agents Chemother       Date:  1983-01       Impact factor: 5.191

6.  Liquid-chromatographic determination of fleroxacin in serum and urine.

Authors:  W M Awni; J A Maloney; K L Heim-Duthoy
Journal:  Clin Chem       Date:  1988-11       Impact factor: 8.327

7.  Pharmacokinetics of aztreonam in patients with gram-negative infections.

Authors:  D M Janicke; R F Cafarell; S W Parker; M A Apicella; W J Jusko
Journal:  Antimicrob Agents Chemother       Date:  1985-01       Impact factor: 5.191

8.  Single- and multiple-dose pharmacokinetics of fleroxacin, a trifluorinated quinolone, in humans.

Authors:  E Weidekamm; R Portmann; K Suter; C Partos; D Dell; P W Lücker
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

9.  RO23-6240, a new orally absorbed quinolone: in vitro comparison with other broad-spectrum oral antimicrobial agents and imipenem.

Authors:  K E Aldridge; D D Schiro; C V Sanders
Journal:  Diagn Microbiol Infect Dis       Date:  1987-05       Impact factor: 2.803

  9 in total
  3 in total

Review 1.  Fleroxacin clinical pharmacokinetics.

Authors:  A E Stuck; D K Kim; F J Frey
Journal:  Clin Pharmacokinet       Date:  1992-02       Impact factor: 6.447

Review 2.  Pharmacokinetics of quinolones: newer aspects.

Authors:  J S Wolfson; D C Hooper
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

Review 3.  Fleroxacin. A review of its pharmacology and therapeutic efficacy in various infections.

Authors:  J A Balfour; P A Todd; D H Peters
Journal:  Drugs       Date:  1995-05       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.